Table 2.
FEV1 Measures
| Subject Group | Mean, liters ± SD | Median, liters | Range, liters (min - max) |
|---|---|---|---|
|
Baseline FEV1 |
|||
| All patients (n = 95) |
1.40 ± 0.71 |
1.19 |
3.09 (0.44 - 3.53) |
| ceftaz/tobra treated (n = 50) |
1.37 ± 0.71 |
1.13 |
3.09 (0.44 - 3.53) |
| mero/tobra treated (n = 45) |
1.44 ± 0.71 |
1.37 |
2.99 (0.48 - 3.47) |
| FEV1 ≥ 70% predicted (n = 11) |
2.46 ± 0.87 |
2.72 |
2.38 (1.15 - 3.53) |
| FEV1 40% - 69% predicted (n = 46) |
1.54 ± 0.56 |
1.47 |
2.52 (0.56 - 3.08) |
| FEV1 < 40% predicted (n = 38) |
0.93 ± 0.30 |
0.90 |
1.43 (0.44 - 1.87) |
|
Observed Peak FEV1 |
|||
| All patients |
1.95 ± 0.87 |
1.72 |
3.62 (0.67 - 4.29) |
| ceftaz/tobra treated |
1.83 ± 0.85 |
1.55 |
3.29 (0.67 - 3.96) |
| mero/tobra treated |
2.09 ± 0.88 |
1.78 |
2.99 (0.48 - 4.29) |
| FEV1 ≥ 70% predicted |
3.17 ± 1.01 |
3.71 |
2.99 (1.30 - 4.29) |
| FEV1 40% - 69% predicted |
2.05 ± 0.71 |
2.05 |
2.76 (0.84 - 3.60) |
| FEV1 < 40% predicted |
1.48 ± 0.59 |
1.39 |
2.44 (0.67 - 3.11) |
|
FEV1 Change, Baseline to Peak |
|||
| All patients |
0.55 ± 0.43 |
0.46 |
2.19 (0.0 - 2.19) |
| ceftaz/tobra treated |
0.46 ± 0.36 |
0.39 |
1.50 (0.05 - 1.55) |
| mero/tobra treated |
0.65 ± 0.49 |
0.55 |
2.19 (0.0 - 2.19) |
| FEV1 ≥ 70% predicted |
0.70 ± 0.46 |
0.43 |
1.40 (0.15 - 1.55) |
| FEV1 40% - 69% predicted |
0.51 ± 0.41 |
0.46 |
2.19 (0.0 - 2.19) |
| FEV1 < 40% predicted | 0.56 ± 0.45 | 0.43 | 1.93 (0.01 - 1.94) |